Abstract
Specific targeting of tumor cells may be achieved by using monoclonal antibodies to tumor antigens. Edrecolomab is a mouse-derived monoclonal IGg2A antibody directed against the human tumor-associated CO17-1A (or Ep-CAM) antigen, and is the first monoclonal antibody approved for cancer therapy. Encouraging results of several clinical trials were recently reported using edrecolomab for adjuvant therapy after surgery of Duke's C colorectal cancer. Side effects and toxicity profiles compare favorably to conventional regimens of radio- or chemotherapy. Future challenges lie in further improvement of these novel therapeutics, hopefully generating benefit for a larger number of cancer patients.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Clinical Trial, Phase III
-
Review
MeSH terms
-
Animals
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / metabolism
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Neoplasm / adverse effects
-
Antibodies, Neoplasm / metabolism
-
Antibodies, Neoplasm / therapeutic use*
-
Antigens, Neoplasm
-
Biotechnology
-
Colorectal Neoplasms / therapy
-
Combined Modality Therapy
-
Humans
-
Immunotherapy / adverse effects
-
Immunotherapy / methods
-
Interferon-gamma / therapeutic use
-
Mice
-
Neoplasms / drug therapy
-
Neoplasms / immunology
-
Neoplasms / therapy*
-
Recombinant Proteins
Substances
-
Antibodies, Monoclonal
-
Antibodies, Neoplasm
-
Antigens, Neoplasm
-
Recombinant Proteins
-
carcinoma-associated antigen 17-1A
-
Interferon-gamma